Evidence map›Paper›PMID 35812046›Full record

ArticleAmerican journal of cancer research2022

The clinicopathological characteristics of early-onset gastric cancer and its evolutionary trends: a retrospective study.

Xiaodong Qu, Xingyu Zhao, Yuhuan Liu, Na Wang, Luyao Zhang, Xiaojing Zhu, Qiang Dong, Junye Liu, Yongquan Shi

Registry-linked trialAbstract read
In one paragraph

Article in American journal of cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07018063 (Efficacy and Safety of Neoadjuvant Nab-Paclitaxel Combined With Oxaliplatin, S-1, and Sintilimab in Patients With Locally Advanced Resectable Early-onset Gastric Cancer), which is not on this map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07018063 phase2not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Efficacy and Safety of Neoadjuvant Nab-Paclitaxel Combined With Oxaliplatin, S-1, and Sintilimab in Patients With Locally Advanced Resectable Early-onset Gastric Cancer: A Phase II, Single-Arm, Open-Label Clinical Trial

TypeinterventionalSponsorzhoujingRan2025 to 2030Enrolled35ConditionsGastric (Cardia, Body) Cancer, Stomach Adenocarcinoma, Locally AdvancedArmsnab-paclitaxel, oxaliplatin, S-1, sintilimab, D2 Gastrectomy
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Early- versus late-onset gastroesophageal cancer: real-world outcomes from a 13-year central European cohort study.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Efficacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON-SEOM registry.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2024
    Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xiaodong QuState Key Laboratory of Cancer Biology, Xijing Hospital of Digestive Diseases, Fourth Military Medical University Xi'an, Shaanxi, China.
Xingyu ZhaoState Key Laboratory of Cancer Biology, Xijing Hospital of Digestive Diseases, Fourth Military Medical University Xi'an, Shaanxi, China.
Yuhuan LiuXi'an Medical University Xi'an, Shaanxi, China.
Na WangState Key Laboratory of Cancer Biology, Xijing Hospital of Digestive Diseases, Fourth Military Medical University Xi'an, Shaanxi, China.
Luyao ZhangState Key Laboratory of Cancer Biology, Xijing Hospital of Digestive Diseases, Fourth Military Medical University Xi'an, Shaanxi, China.
Xiaojing ZhuState Key Laboratory of Cancer Biology, Xijing Hospital of Digestive Diseases, Fourth Military Medical University Xi'an, Shaanxi, China.
Qiang DongState Key Laboratory of Cancer Biology, Xijing Hospital of Digestive Diseases, Fourth Military Medical University Xi'an, Shaanxi, China.
Junye LiuDepartment of Radiation Protective Medicine, Fourth Military Medical University Xi'an, Shaanxi, China.
Yongquan ShiState Key Laboratory of Cancer Biology, Xijing Hospital of Digestive Diseases, Fourth Military Medical University Xi'an, Shaanxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although gastric cancer (GC) is most common in the elderly population, the rate of early-onset gastric cancer (EOGC) is increasing each year. In this study, the clinicopathological information of 9,406 patients who underwent GC resection in our institution from 2000 to 2019 was collected. We compared the clinicopathological characteristics between the EOGC group, in which patients were younger than 40, and the control group, summarizing the evolutionary trends of the EOGC group's characteristics. Then, we focused on the characteristics of EOGC in different sex groups and the evolutionary trends of female EOGC patients' clinicopathological characteristics. The results showed that a greater proportion of the EOGC group was female (47.32% vs. 23.53%), had poorly differentiated adenocarcinoma (84.78% vs. 64.11%), gastric antrum cancer (59.38% vs. 50.72%) and signet ring cell carcinoma (21.13% vs. 8.51%). Over the past 20 years, the proportion of EOGC patients with T4 stage (10.71% to 41.74%), N3 stage (0 to 30.73%) and poorly differentiated adenocarcinoma (70.37% to 92.23%) has increased. In the female EOGC group, there were more patients with stage III-IV disease (57.23% vs. 43.22%), T4 stage (35.85% vs. 22.60%), and poorly differentiated adenocarcinoma (91.88% vs. 78.68%). Additionally, the proportions of T4 stage (16.13% to 50.50%), N3 stage (0% to 31.68%), and poorly differentiated adenocarcinoma (69.23% to 98.97%) gradually increased. In conclusion, our study not only identified unique clinicopathological characteristics of EOGC but also revealed the evolutionary trends of these indicators, which may provide some theoretical basis for the prevention and diagnosis of EOGC.

Indexed as

adenocarcinomaclinicopathological characteristicsEarly-onset gastric cancerevolutionary trendssex

Identifiers

PMID35812046
PMCPMC9251691

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.